{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:34:50Z","timestamp":1784770490349,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.hfc.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T19:18:23Z","timestamp":1665170303000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["SGLT2 Inhibitors and Safety in Older Patients"],"prefix":"10.1016","volume":"18","author":[{"given":"Rena","family":"Pollack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.hfc.2022.03.002_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2022.03.002_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hfc.2022.03.002_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2022.03.002_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.hfc.2022.03.002_bib5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hfc.2022.03.002_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2022.03.002_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-REDUCED trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2022.03.002_bib8","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2022.03.002_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: a narrative review of the literature","volume":"12","author":"Zazzara","year":"1999","journal-title":"Eur Geriatr Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.002_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s41999-021-00471-x","article-title":"Underprescription of medications in older adults: causes, consequences and solutions-a narrative review","volume":"12","author":"Lombardi","year":"2021","journal-title":"Eur Geriatr Med"},{"issue":"10","key":"10.1016\/j.hfc.2022.03.002_bib12","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.hfc.2022.03.002_bib13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1463-1326.2010.01216.x","article-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.hfc.2022.03.002_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.hfc.2022.03.002_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2022.03.002_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.hfc.2022.03.002_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.hfc.2022.03.002_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2022.03.002_bib20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","author":"Jackson","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2022.03.002_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diabetes Vasc Dis Res"},{"issue":"8","key":"10.1016\/j.hfc.2022.03.002_bib22","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus","volume":"37","author":"Kinduryte Schorling","year":"2020","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.002_bib23","first-page":"543","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"Wiley Online Libr"},{"issue":"12","key":"10.1016\/j.hfc.2022.03.002_bib24","first-page":"2276","article-title":"Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: a pooled analysis of phase III studies","volume":"22","author":"Pratley","year":"2020","journal-title":"Wiley Online Libr"},{"issue":"2","key":"10.1016\/j.hfc.2022.03.002_bib25","first-page":"340","article-title":"Obesity undefined, 2019\u200f undefined. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis","volume":"21","author":"Cahn","year":"2018","journal-title":"Wiley Online Libr"},{"issue":"12","key":"10.1016\/j.hfc.2022.03.002_bib26","doi-asserted-by":"crossref","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLOS Med"},{"issue":"14","key":"10.1016\/j.hfc.2022.03.002_bib27","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1503\/cmaj.191283","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study","volume":"192","author":"Iskander","year":"2020","journal-title":"CMAJ"},{"issue":"10","key":"10.1016\/j.hfc.2022.03.002_bib28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium\u2013glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.hfc.2022.03.002_bib29","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/dom.14041","article-title":"Safety of dapagliflozin in a broad population of patients with type 2 diabetes: analyses from the DECLARE-TIMI 58 study","volume":"22","author":"Cahn","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.hfc.2022.03.002_bib30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.hfc.2022.03.002_bib31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2022.03.002_bib32","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.hfc.2022.03.002_bib33","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with sglt2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.hfc.2022.03.002_bib34","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc22-S016","article-title":"16. Diabetes care in the hospital: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.hfc.2022.03.002_bib35","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/dom.14422","article-title":"Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?","volume":"23","author":"Kuhre","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"10.1016\/j.hfc.2022.03.002_bib36","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/14656566.2021.1912735","article-title":"Careful use to minimize adverse events of oral antidiabetic medications in the elderly","volume":"22","author":"Scheen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"Supplement_1","key":"10.1016\/j.hfc.2022.03.002_bib37","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.2337\/dc22-S013","article-title":"13. older adults: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.002_bib38","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.dsx.2021.04.017","article-title":"Type 2 diabetes and bone fragility- An under-recognized association","volume":"15","author":"Farooqui","year":"2021","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"21","key":"10.1016\/j.hfc.2022.03.002_bib39","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.hfc.2022.03.002_bib40","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.002_bib41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.hfc.2022.03.002_bib42","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s00198-020-05590-y","article-title":"Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials","volume":"31","author":"Qian","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.002_bib43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.hfc.2022.03.002_bib44","doi-asserted-by":"crossref","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","article-title":"Association of sodium-glucose cotransporter\u20132 inhibitors with fracture risk in older adults with type 2 diabetes","volume":"4","author":"Zhuo","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.hfc.2022.03.002_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.hfc.2022.03.002_bib46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"issue":"4","key":"10.1016\/j.hfc.2022.03.002_bib47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.hfc.2022.03.002_bib48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.hfc.2022.03.002_bib49","first-page":"2394","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Wiley Online Libr"},{"issue":"1","key":"10.1016\/j.hfc.2022.03.002_bib50","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation","volume":"8","author":"McGovern","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.hfc.2022.03.002_bib51","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.hfc.2022.03.002_bib52","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.hfc.2022.03.002_bib53","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/dc20-0267","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study","volume":"43","author":"Yu","year":"2020","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.hfc.2022.03.002_bib54","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/03007995.2020.1840340","article-title":"Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes\u2013exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations","volume":"36","author":"Alshnbari","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.hfc.2022.03.002_bib55","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes Metab"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:42:34Z","timestamp":1761554554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713622000174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1551713622000174"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2022.03.002","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitors and Safety in Older Patients","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}